EUVIMEDEUVIMED entdecken
Crossref

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity

Morgane Cheminant, Thomas A Fox iD, Mickael Alligon, Olivier Bouaziz, Bénédicte Neven, Despina Moshous iD, Stéphane Blanche, Aurélien Guffroy, Claire Fieschi iD, Marion Malphettes, Nicolas Schleinitz, Antoinette Perlat und 18 weitere

Blood · 2023

DOI: 10.1182/blood.2022015482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Morgane Cheminant und 29 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Haematology, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (alloSCT) is curative for severe inborn errors of immunity (IEIs), with recent data suggesting alloSCT in adulthood is safe and effective in selected patients. However, questions remain regarding the indications for and optimal timing of transplant. We retrospectively compared outcomes of transplanted vs matched nontransplanted adults with severe IEIs. Seventy-nine patients (aged ≥ 15 years) underwent alloSCT between 2008 and 2018 for IEIs such as chronic granulomatous disease (n = 20) and various combined immune deficiencies (n = 59). A cohort of nontransplanted patients from the French Centre de Référence Déficits Immunitaires Héréditaires registry was identified blindly for case-control analysis, with ≤3 matched controls per index patient, without replacement. The nontransplanted patients were matched for birth decade, age at last review greater than index patient age at alloSCT, chronic granulomatous disease or combined immune deficiencies, and autoimmune/lymphoproliferative complications. A total of 281 patients were included (79 transplanted, 202 nontransplanted). Median age at transplant was 21 years. Transplant indications were mainly lymphoproliferative disease (n = 23) or colitis (n = 15). Median follow-up was 4.8 years (interquartile range, 2.5-7.2). One-year transplant-related mortality rate was 13%. Estimated disease-free survival at 5 years was higher in transplanted patients (58% vs 33%; P = .007). Nontransplanted patients had an ongoing risk of severe events, with an increased mean cumulative number of recurrent events compared with transplanted patients. Sensitivity analyses removing patients with common variable immune deficiency and their matched transplanted patients confirm these results. AlloSCT prevents progressive morbidity associated with IEIs in adults, which may outweigh the negative impact of transplant-related mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatous Disease, ChronicHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansAdultYoung AdultRetrospective StudiesConservative TreatmentTransplantation, HomologousStem Cell TransplantationTransplantation Conditioning

Autor:innen und Institutionen

  • Clinical Haematology, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Laboratory of Hematological Disorders, Université Paris Cité, Institut Imagine, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
  • Centre de Référence Déficits Immunitaires Héréditaires, Paris, France.
  • University College London Institute of Immunity and Transplantation, University College London, London, United Kingdom.
  • Department of Immunology, Royal Free London National Hospital Service Foundation Trust, London, United Kingdom.
  • Department of Haematology, University College London Hospitals National Hospital Service Foundation Trust, London, United Kingdom.

ORCID-Profile: Thomas A Fox, Despina Moshous, Claire Fieschi, Jean-François Viallard, Sébastien Humbert, Vincent Barlogis, Benjamin Carpenter, Arian Laurence, Ambroise Marçais, Ronjon Chakraverty, Emma C Morris

Zitieren

APA

Cheminant, M., Fox, T. A., Alligon, M., Bouaziz, O., Neven, B., Moshous, D., Blanche, S., Guffroy, A., Fieschi, C., Malphettes, M., Schleinitz, N., Perlat, A., Viallard, J. F., Dhedin, N., Sarrot-Reynauld, F., Durieu, I., Humbert, S., Fouyssac, F., Barlogis, V., …, & Suarez, F. (2023). Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood. https://doi.org/10.1182/blood.2022015482

Vancouver

Cheminant M, Fox TA, Alligon M, Bouaziz O, Neven B, Moshous D, et al. Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood. 2023. doi:10.1182/blood.2022015482

BibTeX
@article{Cheminant2023,
  author = {Cheminant, Morgane and Fox, Thomas A and Alligon, Mickael and Bouaziz, Olivier and Neven, Bénédicte and Moshous, Despina and Blanche, Stéphane and Guffroy, Aurélien and Fieschi, Claire and Malphettes, Marion and Schleinitz, Nicolas and Perlat, Antoinette and Viallard, Jean-François and Dhedin, Nathalie and Sarrot-Reynauld, Françoise and Durieu, Isabelle and Humbert, Sébastien and Fouyssac, Fanny and Barlogis, Vincent and Carpenter, Benjamin and Hough, Rachael and Laurence, Arian and Marçais, Ambroise and Chakraverty, Ronjon and Hermine, Olivier and Fischer, Alain and Burns, Siobhan O and Mahlaoui, Nizar and Morris, Emma C and Suarez, Felipe},
  title = {Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022015482}
}
Kostenlos starten →